A recent study confirmed that the order of mutations has relevant implications in MPN-SVT patients, since cases where JAK2 mutations occurred first have already been demonstrated to be typically associated with an increased risk of thrombosis [75]. Here, JAK2 is linked to myeloproliferative neoplasm.